BioCentury
ARTICLE | Company News

Celtrix news

November 21, 1994 8:00 AM UTC

The Santa Clara company cut its staff to 100 from 150 and postponed its pre-marketing activities in response to the disappointing three-month follow-up data from its Phase III study of BetaKine TGF-beta-2 to treat macular holes. ...